Roche Annual General Meeting 2019
05 Março 2019 - 10:23AM
F. Hoffmann-La Roche Ltd / Roche Annual General Meeting 2019 .
Processed and transmitted by West Corporation. The issuer is solely
responsible for the content of this announcement.
-
All proposals of the Board of
Directors approved
-
Christoph Franz as Chairman of
the Roche Board of Directors and all other Board members standing
for re-election approved; Professor Dr Hans Clevers elected as a
new member of the Board of Directors
-
32th consecutive dividend
increase to CHF 8.70 per share approved
Basel, 05 March 2019 - Roche (SIX: RO, ROG; OTCQX:
RHHBY) today announced that its shareholders approved all proposals
of the Board of Directors at its ordinary Annual General Meeting
(AGM). The 840 attending shareholders, representing 86.73% of the
total of 160,000,000 shares, approved the Management Report, the
Financial Statements and the Consolidated Financial Statements for
2018.
Christoph Franz was confirmed as Chairman of the Board of Directors
with 99.89% of the votes.
"2018 was a very strong year for Roche. Almost 90% of our growth
came from newly launched products, demonstrating that we are
successfully rejuvenating our portfolio. I am confident that we are
well positioned for the future by pursuing our strategy of
systematic innovation," said Christoph Franz, Chairman of Roche's
Board of Directors. "I am delighted that Professor Dr Hans Clevers
has been elected as a new member of the Board of Directors. He will
strengthen the Board of Directors with his many years of expertise
and experience in medical research."
Shareholders also authorised the ratification of the Board of
Directors' actions and approved an increase in the gross dividend
for the past financial year to 8.70 Swiss francs (gross) per share
and non-voting equity security. This is the 32th consecutive
dividend increase.
Shareholders endorsed the total amount of bonuses paid to the
Corporate Executive Committee for 2018 with 99.59% of the votes, as
well as the bonus paid to the Chairman of the Board of Directors
for 2018, which was approved by 99.45% of the votes. They also
approved the maximum total amount of future remuneration of the
Board of Directors, which was confirmed by 99.60% of the votes, and
the maximum total amount of future remuneration for the Corporate
Executive Committee until the 2020 ordinary Annual General Meeting
by 99.59% of the votes.
In addition to Christoph Franz, all other Board members who stood
for re-election were confirmed for a term of one year:
Professor. Dr. Hans Clevers was elected as a new member of the
Board of Directors for a term of one year.
The following Board members were elected to the Remuneration
Committee:
The amendment to the Articles of Association proposed by the Board
of Directors regarding Stock-settled Stock Appreciation Rights
(S-SARs) and Restricted Stock Units (RSUs) was also approved with
99.60% of the votes represented.
KPMG AG was elected as external auditor for the financial year 2019
and BDO AG was elected as independent voting proxy until the
conclusion of the next regular AGM in 2020.
About Roche
Roche is a
global pioneer in pharmaceuticals and diagnostics focused on
advancing science to improve people's lives. The combined strengths
of pharmaceuticals and diagnostics under one roof have made Roche
the leader in personalised healthcare - a strategy that aims to fit
the right treatment to each patient in the best way
possible.
Roche is the world's largest biotech company, with truly
differentiated medicines in oncology, immunology, infectious
diseases, ophthalmology and diseases of the central nervous system.
Roche is also the world leader in in vitro diagnostics and
tissue-based cancer diagnostics, and a frontrunner in diabetes
management.
Founded in 1896, Roche continues to search for better ways to
prevent, diagnose and treat diseases and make a sustainable
contribution to society. The company also aims to
improve patient access to medical innovations by working with
all relevant stakeholders. Thirty medicines developed by Roche are
included in the World Health Organization Model Lists of Essential
Medicines, among them life-saving antibiotics, antimalarials and
cancer medicines. Moreover, for the tenth consecutive year, Roche
has been recognised as the most sustainable company in the
Pharmaceuticals Industry by the Dow Jones Sustainability Indices
(DJSI).
The Roche Group, headquartered in Basel, Switzerland, is active in
over 100 countries and in 2018 employed about 94,000 people
worldwide. In 2018, Roche invested CHF 11 billion in R&D and
posted sales of CHF 56.8 billion. Genentech, in the United
States, is a wholly owned member of the Roche Group. Roche is the
majority shareholder in Chugai Pharmaceutical, Japan. For more
information, please visit www.roche.com.
All trademarks used or mentioned in this release are protected by
law.
Roche Group Media Relations
Phone: +41 61 688 8888 / e-mail:
media.relations@roche.com
- Nicolas Dunant (Head)
- Patrick Barth
- Ulrike Engels-Lange
- Simone Oeschger
- Anja von Treskow
20190305_MR_AGM_English
This
announcement is distributed by West Corporation on behalf of West
Corporation clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the
information contained therein.
Source: F. Hoffmann-La Roche Ltd via Globenewswire
--- End of Message ---
F. Hoffmann-La Roche Ltd
Grenzacherstrasse 124 Basel Switzerland
ISIN: CH0012032113;
Rogers (NYSE:ROG)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024
Rogers (NYSE:ROG)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024